Mechanism underlying the reversal of contractility dysfunction in experimental colitis by cyclooxygenase-2 inhibition.
Inflammatory bowel diseases are associated with reduced colonic contractility and induction of cyclooxygenase-2. In this study a possible role of cyclooxygenase-2 in and the underlying mechanism of the reduced contractility were investigated in experimental colitis. The effects of meloxicam, a cyclooxygenase-2 selective inhibitor were examined on colonic contractility and MAP kinase p38 and ERK(1/2) expression. Colitis was induced in Sprague-Dawley male rats by intra-colonic instillation of trinitrobenzenesulphonic acid (TNBS; 40 mg/rat in 50 ethanol). The animals were divided into three groups. Group 1 (n=9) received meloxicam (3 mg/kg-day) gavage 1 h before and 1 day (Group 2) after induction of colitis. Group 3 (n=9) received phosphate buffered saline (PBS) in a similar manner and served as colitic control. The non colitic control animals received meloxicam in a similar manner. The animals were sacrificed after 5 days of treatment, colon was cleaned with PBS and colonic smooth muscle was obtained which was used in this study. Meloxicam treatment given 1 h before or 1 day after administration of colitis restored the reduced colonic contractility without affecting the sensitivity to carbachol. The levels of colonic smooth muscle IL-1beta mRNA, PGE(2), ERK(1/2), p38, malondialdehyde, myeloperoxidase activity and colonic mass were increased, whereas the body weight was decreased due to TNBS. The changes except colonic muscle mass and p38 expression were reversed by meloxicam treatment. These findings indicate that restoration of reduced colonic contractility by meloxicam is mediated by ERK(1/2), and that ERK(1/2) may serve as an important anti inflammatory target for treatment of colitis.
Khan
I
I
Department of Biochemistry, Faculty of Medicine, Kuwait University, PO Box 24923, Kuwait, Kuwait. Islam@hsc.edu.kw
Oriowo
M A
MA
D000818:Animals; D015153:Blotting, Western; D002217:Carbachol / Q000494:pharmacology; D003092:Colitis / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology; D003106:Colon / Q000187:drug effects / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D048049:Extracellular Signal-Regulated MAP Kinases / Q000096:biosynthesis; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007537:Isometric Contraction / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D000077239:Meloxicam; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D014302:Trinitrobenzenesulfonic Acid; D048051:p38 Mitogen-Activated Protein Kinases / Q000096:biosynthesis
D052246:Cyclooxygenase 2 Inhibitors; D012333:RNA, Messenger; D013843:Thiazines; D013844:Thiazoles; D008315:Malondialdehyde; D014302:Trinitrobenzenesulfonic Acid; D002217:Carbachol; D009195:Peroxidase; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D000077239:Meloxicam